(Q38007133)

26 August 2017

title

Progress in cancer therapy targeting c-Met signaling pathway (English)

1 reference

26 August 2017

Kyung Hee Jung

1

1 reference

26 August 2017

Byung Hee Park

series ordinal

2

1 reference

26 August 2017

Soon-Sun Hong

series ordinal

3

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Archives of Pharmacal Research

26 August 2017

published in

1 reference

26 August 2017

volume

35

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

595-604

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Cross-talk between the proto-oncogenes Met and Ron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Showering c-MET-dependent cancers with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

The Sema domain of Met is necessary for receptor dimerization and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Expression and mutational analysis of MET in human solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Mechanisms and significance of bifunctional NK4 in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Activation of the JNK pathway is essential for transformation by the Met oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Negative feedback regulation of Met-dependent invasive growth by Notch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

MET signalling: principles and functions in development, organ regeneration and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Evidence for the identity of human scatter factor and human hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0402-6

10.1007/S12272-012-0402-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1005295122

0 references

1 reference